分子病理检测在卵巢粒层细胞瘤鉴别诊断中的应用  

Application of molecular testing detection in the differential diagnosis of granulosa cell tumors

作　　者：姜宇慧 JIANG Yu-hui(Sujiatun District Central Hospital,Shenyang 110000,China)

机构地区：[1]苏家屯区中心医院,110000

出　　处：《中国实用医药》2022年第4期81-83,共3页China Practical Medicine

摘　　要：目的评价分子病理检测在卵巢粒层细胞瘤鉴别诊断中的应用效果。方法 50例卵巢粒层细胞瘤患者,均进行分子病理检测,观察患者FOXL2、AKT1、以及DICER1突变情况,并且对患者成年型粒层细胞瘤(AGCT)预后情况作出评估。结果 50例患者FOXL2、AKT1、DICER1突变情况表现如下:2例卵泡膜纤维瘤,4例卵巢两侧母细胞瘤,5例其他卵巢性索间质瘤。患者卵巢纤维瘤FOXL2突变明显增高,同时在患者AKT1突变分析过程中得出,突变情况表现无明显变化。而在DICER1突变情况分析过程中得出,患者有明显的高分化DICER1突变症状出现,所得出的各项数据有明显差异,其突变类型主要表现为弥漫性、微滤泡型以及岛型,可见核沟。且研究证实,在随访6~36个月后患者预后情况如下:有6例患者在预后过程中发病,其发病间隔时间为13个月,有12例患者有明显的突变情况,并且经国际妇产科联盟(FIGO)诊断为Ⅲ期c阶段,给予患者手术化疗后患者预后情况相对较好。有12例患者预后表现为24个月以后复发,其病理分为其Ⅰ期a阶段,在随访结束时50例患者均正常存活。结论在卵巢粒层细胞瘤鉴别诊断过程中,为患者进行分子病理检测的价值较高,能够满足患者的检测需求,所以可将其推广到临床。Objective To evaluate the application effect of molecular pathology testing in the differential diagnosis of granuloseacel tumors.Methods In 50 patients with ovarian granulosa cell tumors,molecular pathology was performed to observe FOXL2,AKT1,and DICER1 mutations,and to assess the prognosis of adult granulosa cell tumors(AGCT).Results The mutations of FOXL2,AKT1,and DICER1 in 50 patients were as follows:2 cases of follicular membrane fibroma,4 cases of bilateral ovarian blastoma,and 5 cases of other ovarian sex cord stromal tumors.The FOXL2 mutation of the patient’s ovarian fibroma was significantly increased.At the same time,it was found during the analysis of the patient’s AKT1 mutation that there was no significant change in the mutation.In the analysis of the DICER1 mutation situation,it was concluded that the patient had obvious symptoms of well-differentiated DICER1 mutation,the resulting data were significantly different,and the mutation type was mainly diffuse,microfollicular type and island type,with visible nuclear grooves.Studies confirmed that the prognosis of patients after 6-36 months of follow-up was as follows:6 patients developed symptoms during the prognostic process,the interval between onsets was 13 months,and 12 patients had obvious mutations,and were tested by Intemational Federation of Gynecology and Obstetrics(FIGO) diagnosed as stage Ⅲc,and the prognosis of patients after surgery and chemotherapy was relatively good.The prognosis of 12 patients showed recurrence after 24 months,and their pathology classified as stage Ⅰa.At the end of follow-up,all 50 patients were alive.Conclusion In the differential diagnosis of granulosa cell tumors,molecular pathology testing is of high value for patients,and can meet the testing needs of patients,so it can be extended to the clinic.

关 键 词：分子病理检测 卵巢粒层细胞瘤 鉴别诊断 应用方法 效果评价 

分 类 号：R737.31[医药卫生—肿瘤]